TRELANSERIN

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H24FN5O2S
Molecular Weight	465.543
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)CN1C(=O)C=C(CCN2CCN(CC2)C3=NC=CC4=C3C=CS4)C5=C1C=C(F)C=C5

InChI

InChIKey=JDLYOFUDIKMYBL-UHFFFAOYSA-N

InChI=1S/C24H24FN5O2S/c25-17-1-2-18-16(13-23(32)30(15-22(26)31)20(18)14-17)4-7-28-8-10-29(11-9-28)24-19-5-12-33-21(19)3-6-27-24/h1-3,5-6,12-14H,4,7-11,15H2,(H2,26,31)

HIDE SMILES / InChI

Molecular Formula	C24H24FN5O2S
Molecular Weight	465.543
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11504649 | https://www.ncbi.nlm.nih.gov/pubmed/12909202 | https://www.ncbi.nlm.nih.gov/pubmed/15321735 | https://apps.who.int/iris/bitstream/handle/10665/275695/WHO-EMP-RHT-TSN-2018.1-eng.pdf

Trelanserin, also known as SL-650472, is a serotonin 5-HT2A and 5-HT1B receptors antagonist. It was predicted to be histamine receptor H1 antagonist too. Trelanserin blocked serotonin-induced increases in blood pressure, rate pressure product and circumflex coronary artery flow and reduced serotonin-induced ischemic myocardial segment length shortening. Thus, trelanserin opposes serotonin-induced myocardial dysfunction in a dog model of exercise-induced ischemia. Trelanserin also blocked sumatriptan-induced vasoconstriction in ischemic and normally perfused hindlimbs in dogs.

Approval Year

PubMed

Title	Date	PubMed
Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput Data.	2016-08	26978842
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.	2014-06	24837663
Overcoming the obstacles in the pharma/biotech industry: 2008 update.	2009-02-12	19209298
Serotonin aggravates exercise-induced cardiac ischemia in the dog: effect of serotonin receptor antagonists.	2004-08-16	15321735
SL65.0472 blocks 5-hydroxytryptamine-induced vasoconstriction in a dog hindlimb ischemia model.	2003-08-01	12909202
Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat.	2002-11	12393100
Synthesis and SAR of 3- and 4-substituted quinolin-2-ones: discovery of mixed 5-HT(1B)/5-HT(2A) receptor antagonists.	2001-08	11504649
Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist.	2001-03-02	11239927
Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.	2001-03	11307825

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:33:45 GMT 2025` Edited by `admin` on `Mon Mar 31 18:33:45 GMT 2025`
Record UNII	QUD44MBL5S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SL-650472

Preferred Name

English

TRELANSERIN

Official Name

English

PYRIDIN-4-YL)PIPERAZIN-1-YL)ETHYL)-1,2-DIHYDROQUINOLIN-1-YL)ACETAMIDE

Common Name

English

SL65.0472

Code

English

SL650472

Code

English

trelanserin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885